F2RL1 and pancreatic adenocarcinoma: In this study, the human pancreatic adenocarcinoma cell line SW1990 was treated in vitro with the anti-PAR-2 agonist peptide (Val-Lys-Gly-Ile-Leu-Ser; VKGILS), trypsin or the PAR-2 agonist (Ser-Leu-Ile-Gly-Lys-Val; SLIGKV).